Press Release
Jerini receives european commission approval for FIRAZYR® (Icatibant) in HAE treatment
Tuesday, July 15 2008
Shire Limited, the global specialty biopharmaceutical company, notes that Jerini AG has announced today that the European Commission has granted the company marketing authorization for its lead compound FIRAZYR® (Icatibant) in the treatment of acute attacks of hereditary angioedema (HAE).
HAE is a debilitating and potentially life-threatening genetic disease characterized by spontaneous and recurring attacks of edema.
As announced by Shire on 3 July, 2008, Maia Elfte Vermögensverwaltungs-GmbH, to be renamed "Shire Deutschland Investments GmbH", a German indirect subsidiary of Shire Limited, has launched a voluntary public takeover offer for all shares in Jerini AG.
Jerini's Supervisory and Management Boards unanimously support the transaction and are recommending acceptance of the offer to its shareholders. Subject to completion of certain sale and purchase agreements and registration of the newly issued shares, Shire will have rights to approximately 75% of Jerini’s share capital before the receipt of any takeover offer acceptances.
It is anticipated that the offer will be open for acceptance by the remaining shareholders until the end of Q3 2008 and is contingent upon the fulfilment of certain customary terms and conditions, including approval by relevant merger control authorities.
The European Commission’s approval allows Jerini to market FIRAZYR in the European Union’s 27 member states, making it the first product to be approved in all EU countries for the treatment of HAE.
Sylvie Gregoire, President of Shire Human Genetic Therapies (HGT) business commented, "We are very pleased that European approval has been granted to Jerini today. This is an important step in bringing this first in class orphan treatment to patients who suffer from HAE attacks.
"We look forward to the completion of our transaction with Jerini which will enable us to work together and ultimately build FIRAZYR into a global gold standard treatment."
Latest Press Releases
- Shire delivers strong quarter driven by 3m of new product sales
- Jerini receives european commission approval for FIRAZYR® (Icatibant) in HAE treatment
- Shire to add new orphan drug to its HGT portfolio - EU launch imminnent
- Graham Hetherington appointed Chief Financial Officer and Board Director at Shire
- First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide
- Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
- Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair
- Publication of Supplementary Prospectus
- Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
- FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Spread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.
